Skip to content
    Drishti.money
    Earnings calls

    SPARC concall ledger

    Every earnings call for SPARC — management tone, guidance, KPIs and promise tracking, quarter by quarter.

    SPARC · 5 transcripts · Healthcare · latest Q2 FY26
    Q2 FY26Published 08 Jan 2026Call held 08 Jan 2026

    SPARC Q2 FY26 Earnings Call Transcript & Analysis

    Cumulative Promoter Debt45 million_dollarsAnnual Fixed Cost Savings10 million_dollarsProjected Operational Spend29 million_dollarsPrevious Operational Spend31 million_dollars

    Cumulative Promoter Debt 45 million_dollars; Annual Fixed Cost Savings 10 million_dollars; Projected Operational Spend 29 million_dollars. SPARC has undergone a strategic reset, narrowing therapeutic focus to oncology and immunology.

    Read full transcript & analysis
    Q3 FY24Published 18 Apr 2024Call held 18 Apr 2024

    SPARC Q3 FY24 Earnings Call Transcript & Analysis

    PROSEEK Trial Budget45 million USDPROSEEK Trial Spend35 million USDCurrent Cash Balance20 million USDCash Runway12 months

    PROSEEK Trial Budget 45 million USD; PROSEEK Trial Spend 35 million USD; Current Cash Balance 20 million USD. Vodobatinib PROSEEK trial for Parkinson's Disease failed to meet primary and key secondary endpoints in interim analysis of 442 patients by March 2024.

    Read full transcript & analysis